CRISPR Therapeutics Earnings Reports

CRISPR Therapeutics posted a net loss of $106.4 million in Q3 2025 on revenue of $889,000. While R&D costs declined year-over-year, collaboration expenses rose significantly. The company maintains a strong cash position of $1.9 billion and continues advancing multiple clinical programs.

CRISPR Therapeutics reported a net loss of $136.0 million for Q1 2025, compared to a net loss of $116.6 million for Q1 2024. The company's total revenue for the quarter was $865 thousand, primarily from grant revenue. Research and development expenses decreased, while general and administrative and collaboration expenses increased.

CRISPR Therapeutics reported a net loss of $85.9 million for the third quarter of 2024, compared to a net loss of $112.2 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities were $1,935.6 million as of September 30, 2024.

CRISPR Therapeutics reported its Q2 2024 financial results, highlighting progress in its pipeline and the continued launch of CASGEVY™. The company's cash position remains strong with approximately $2 billion in cash, cash equivalents, and marketable securities.

CRISPR Therapeutics reported its Q1 2024 financial results, highlighted by a strong cash position of approximately $2.1 billion. The company is advancing its portfolio of clinical trials and nominated additional in vivo programs.

CRISPR Therapeutics reported a net income of $89.3 million for Q4 2023, a significant turnaround from the net loss of $110.6 million in Q4 2022. The company's cash position remains strong, with over $2.1 billion in pro-forma cash, cash equivalents, and marketable securities as of February 21, 2024, bolstered by a registered direct offering and milestone payments. The company continues to advance its pipeline, including CASGEVY™ and next-generation CAR T cell programs.

CRISPR Therapeutics reported its Q3 2023 financial results, showing a net loss of $112.2 million compared to a net loss of $174.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $1,739.8 million as of September 30, 2023. Significant progress was noted across its clinical pipeline, especially with exa-cel awaiting FDA decision.

CRISPR Therapeutics reported a net loss of $77.7 million for the second quarter of 2023, with total collaboration revenue of $70.0 million. The FDA accepted BLAs for exa-cel for severe SCD and TDT, marking significant progress towards delivering innovative gene-edited therapies.

CRISPR Therapeutics reported financial results for the first quarter ended March 31, 2023. The company continued to advance its portfolio programs, including regulatory submissions for exa-cel and initiation of clinical trials for next-generation CAR T candidates.

CRISPR Therapeutics reported its Q4 and full year 2022 financial results, highlighting the completion of regulatory submissions for exa-cel in Europe and ongoing clinical trials for CTX110 and CTX130. The company is also advancing its regenerative medicine and in vivo programs. While collaboration revenue was not material for the quarter, R&D expenses were $103.6 million. The company's cash position remains strong at $1,868.4 million.

CRISPR Therapeutics reported its Q3 2022 financial results, highlighting progress in its clinical pipeline, including exa-cel's regulatory submissions and advancements in immuno-oncology and regenerative medicine programs.

CRISPR Therapeutics reported a collaboration revenue of $0.2 million for the second quarter of 2022, compared to $900.2 million for the second quarter of 2021. R&D expenses were $123.2 million, compared to $82.3 million for the second quarter of 2021. Net loss was $185.8 million for the second quarter of 2022, compared to net income of $759.2 million for the second quarter of 2021. Cash, cash equivalents and marketable securities were $2,073.7 million as of June 30, 2022, compared to $2,379.1 million as of December 31, 2021.

CRISPR Therapeutics reported its Q1 2022 financial results, with a cash position of $2,221.3 million. The company's total collaboration revenue was $0.2 million. R&D expenses increased to $118.2 million, and G&A expenses were $28.0 million. The net loss for the quarter was $179.2 million.

CRISPR Therapeutics reported a net loss of $141.2 million for the fourth quarter of 2021, compared to a net loss of $107.0 million for the fourth quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $2,379.1 million as of December 31, 2021. Total collaboration revenue was $12.3 million for the fourth quarter of 2021 compared to $0.2 million for the fourth quarter of 2020.

CRISPR Therapeutics reported a net loss of $127.2 million for the third quarter of 2021, compared to a net loss of $92.4 million for the third quarter of 2020. Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to $0.1 million for the third quarter of 2020. Cash, cash equivalents and marketable securities were $2,477.4 million as of September 30, 2021, compared to $2,589.4 million as of June 30, 2021.

CRISPR Therapeutics reported a strong second quarter, highlighted by a $900 million upfront payment from Vertex related to their collaboration agreement. The company is progressing its clinical programs, including CTX001 for hemoglobinopathies, and anticipates reporting clinical data from immuno-oncology programs later in the year.

CRISPR Therapeutics reported a net loss of $113.2 million for the first quarter of 2021, compared to a net loss of $69.7 million for the first quarter of 2020. Total collaboration revenue was $0.2 million for the first quarter of 2021, consistent with the first quarter of 2020. Cash, cash equivalents and marketable securities were $1,806.2 million as of March 31, 2021, compared to $1,690.3 million as of December 31, 2020.

CRISPR Therapeutics reported a net loss of $107.0 million for the fourth quarter of 2020, compared to a net income of $30.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities totaled $1,690.3 million as of December 31, 2020.

CRISPR Therapeutics reported positive top-line results from its Phase 1 CARBON trial of CTX110, received FDA designations for CTX001 and CTX120, and began treating patients in CTX130 trials. The company's cash position increased due to a public offering, but collaboration revenue decreased significantly, leading to a net loss for the quarter.

CRISPR Therapeutics reported a net loss of $79.7 million for the second quarter of 2020, with total collaboration revenue of less than $0.1 million. Cash and cash equivalents were $945.1 million as of June 30, 2020.

CRISPR Therapeutics reported a net loss of $69.7 million for the first quarter of 2020, with cash and cash equivalents totaling $889.7 million. The company is progressing five cell therapy clinical trials and expects to report data for CTX001 and CTX110 programs this year. A $25 million milestone payment was received from Vertex in April 2020 related to the DM1 program.

CRISPR Therapeutics reported a net income of $30.5 million for the fourth quarter of 2019, a significant improvement compared to a net loss of $47.6 million for the same period in 2018. Total collaboration revenue was $77.0 million, driven by collaboration agreements with Vertex. The company's cash and cash equivalents reached $943.8 million.